Sensus Healthcare, Inc. (Nasdaq: SRTS) reported its financial results for the third quarter of 2026 on November 12, 2026. The company recorded revenues of $6.0 million for the three months ended September 30, 2026. This figure represents a decrease of $0.9 million, or 13.0%, compared to the $6.9 million generated in the same period of the prior year.
The decline in revenue was attributed to a shift in product mix toward lower-priced SRT-100 systems and the absence of sales to a historically large customer. Additionally, three systems shipped during the quarter were under the Fair Deal Agreement program and rental arrangements, where revenue is recognized over the term of the agreement rather than at the time of shipment.
Despite the revenue decrease, the company reported an improvement in gross profit and margins. Gross profit increased to $3.3 million from $2.7 million in the prior-year period. Overall gross margin improved to 55% from 39.1% in the third quarter of 2025. This improvement was driven by a higher proportion of shipments of higher-margin SRT-100 units compared to lower-margin SRT-100 Vision units.
On the expense side, general and administrative expense increased by 21.1% to $2.3 million, primarily due to higher legal and professional fees. Research and development expense decreased by 38.9% to $1.1 million, driven by a reduction in lobbying costs and headcount. Selling and marketing expenses remained flat at $1.5 million.
As of September 30, 2026, the company had cash, restricted cash, and cash equivalents totaling $12.9 million. The company had no outstanding borrowings under its revolving line of credit at that time. The company also noted that it shipped 26 systems during the quarter, including eight carried over from the second quarter of 2026 due to financing approval timing. This marked the shipment of the company's 1,000th SRT system.
